Roche Reaffirms 2026 Outlook Despite Weak Vabysmo Sales, Strong Swiss Franc
Basel: Swiss drugmaker Roche confirmed its 2026 outlook on Thursday after first-half sales fell slightly in Swiss franc…
Sales for Roche’s Vabysmo rise again, but momentum is stalled
While Roche touted sales and market share increases for eye disease drug Vabysmo on Thursday, there is evidence…
Roche Q1 earnings suffer blood bath thanks to currency headwinds
Editor’s Note: The original version of the story was based on consensus estimates cited by ODDO BHF. We’ve…
#AAN26: Roche’s multiple sclerosis pill delays relapse, but liver toxicity could need monitoring
Roche’s multiple sclerosis pill more than doubled patients’ relapse-free interval compared with Sanofi’s marketed MS pill Aubagio, according…
Why Is Pharma Giant Roche Stock Trading Lower On Wednesday?
Roche Holdings AG (OTC:RHHBY) on Wednesday announced data from MUSETTE Phase 3 trial of a high dose of…
![[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth](https://www.europesays.com/ch/wp-content/uploads/2026/02/84b0110bbf60eb8397db0461bc3549c4-380x220.png)
Roche’s fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)
F. Hoffmann-La Roche Ltd Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary…
Roche’s OCREVUS Shows 30% Disability Reduction in Advanced PPMS Trial
Roche (OTCQX:RHHBY) presented new clinical data for OCREVUS and fenebrutinib at ECTRIMS 2025.…
Roche fenebrutinib Phase III hits PPMS disability goal
Roche (OTCQX: RHHBY) reported Phase III FENtrepid results showing investigational oral BTK inhibitor…